Related Experiment Videos
Allergic bronchopulmonary aspergillosis and cystic fibrosis
1Department of Pediatrics, Allergy-Immunology Division, Medical College of Wisconsin, 9000 West Wisconsin Avenue, Milwaukee, WI 53226, USA. mlevy@chw.org
Abstract:
Allergic bronchopulmonary aspergillosis (ABPA) is a disease affecting patients with asthma as well as those with cystic fibrosis. The clinical picture of ABPA is characterized by symptoms of wheezing, pulmonary infiltrates, bronchiectasis, and in later stages, pulmonary fibrosis. Since patients with cystic fibrosis may have several of these clinical features as part of their disease process, it is important to distinguish the overlap of this entity so that therapy may be instituted in a timely manner. This paper will discuss the clinical diagnosis, immuno-pathology and treatment of ABPA as it affects patients with cystic fibrosis.
Insights
Allergic bronchopulmonary aspergillosis (ABPA) is a lung disease that affects patients with asthma and cystic fibrosis. Early diagnosis and treatment are crucial for managing ABPA in cystic fibrosis patients to prevent lung damage.
Area of Science:
- Pulmonology
- Immunology
- Medical Mycology
Background:
- Allergic bronchopulmonary aspergillosis (ABPA) presents with symptoms overlapping those of cystic fibrosis (CF).
- Distinguishing ABPA in CF patients is critical for timely and appropriate therapeutic intervention.
- ABPA can lead to bronchiectasis and pulmonary fibrosis if left untreated.
Purpose of the Study:
- To discuss the clinical diagnosis of ABPA in cystic fibrosis patients.
- To review the immunopathology underlying ABPA in this population.
- To outline current treatment strategies for ABPA in cystic fibrosis.
Main Methods:
- Literature review of clinical diagnosis criteria for ABPA.
- Analysis of immunopathological mechanisms in ABPA.
- Synthesis of treatment guidelines for ABPA in CF.
Main Results:
- ABPA diagnosis in CF requires careful consideration of overlapping symptoms like wheezing and infiltrates.
- Immune responses to Aspergillus fumigatus antigens are central to ABPA pathogenesis.
- Treatment involves antifungal agents and corticosteroids, tailored to CF patient needs.
Conclusions:
- Accurate differentiation of ABPA in CF patients is essential for effective management.
- Understanding ABPA's immunopathology aids in targeted therapy.
- Prompt treatment of ABPA can prevent irreversible lung damage in individuals with cystic fibrosis.